Indian drug giants Ranbaxy Laboratories is facing an existential conundrum with Japanese owners Daiichi Sankyo, thinking of rechristening the company, perhaps in the hope that a name change will give them a blank slate to work …
New Delhi, June 7 (IANS): Backing pharma major Ranbaxy, who has been accused of marketing sub-standard medicines, the health ministry said there was nothing wrong with the quality of its drugs. ‘There are misconceptions about …
The DCGI will complete its preliminary examination into the charges that Ranbaxy pleaded guilty to in the US and whether those infringements have any ramifications in India, health secretary Keshav Desiraju told the Economic …
The Indian Medical Association (IMA) has asked the Drugs Controller General of India (DCGI) to investigate the quality of drugs sold by Ranbaxy Laboratories in India. ‘We will soon be writing to the DCGI asking them to check …
The ramifications of Ranbaxy’s admission of seven federal charges including selling adulterated drugs with intent to defraud and the subsequent fine of $500 million to resolve false claim allegations are starting to be felt in …
Former Ranbaxy Laboratories Chairman Malvinder Singh has hit back at Daiichi Sankyo’s claim that crucial facts about the USFDA investigations were concealed at the time the company was sold by his family and blamed the Japanese …
Daiichi Sankyo, the Japanese owners of Ranbaxy Laboratories are considering taking legal action against former promoters of the Indian drug maker – Malvinder Singh and Shivinder Singh the Economic Times reported. The company …
Indian pharma has taken a big hit with the Ranbaxy episode raising questions about the efficacy and safety of the billion dollar industry. Indian generic drugs are quite popular in the US and other parts of the world but they may …
The United States 2013-14 Budget might actually have more effect on the Indian generic pharmaceutical companies than PC’s budget. The proposal is to increase the budge of the US Food and Drug Administration (FDA) which will …
Zydus Cadila has got the USFDA approval for marketing Pioglitazone, an anti-diabetes drug used in Type 2 diabetes.
Pioglitazone Hydrochloride, acts as an insulin sensitizer and causes the insulin receptors on cells to become …
New Jersey-based Celgene Corporation announced the US Food and Drug Administration (FDA) has approved Abraxane paclitaxel protein-bound particles for injectable suspension (albumin-bound) for the first-line treatment of locally …
Drug-maker Lupin said its subsidiary Lupin Pharmaceuticals Inc has launched cholesterol lowering drug Fenofibrate tablets in 48mg and 145mg strengths in the United States. The Mumbai-based company's Fenofibrate tablets are a …
The United States FDA has given the green light to GVK Bioscience, a contract research organisation’s Ahmedabad unit to carry out bioavailability and bioequivalence studies. The GVK BIO Ahmedabad facility, commissioned in …
The USFDA has approved the first personalized therapy for treatment of colorectal cancer (CRC). Doctors say, more than 42,000 new CRC are estimated to occur in India in 2012. The FDA nod for Erbitux is based on data from a large …
